Thank you for submitting your manuscript for consideration by The EMBO Journal. Three referees have now evaluated it, and their comments are shown below. As you will see, the referees are all positive about the paper and will support its publication here after appropriate revision. I would thus like to invite you to submit a revised version of the manuscript that addresses the points raised by the referees in an adequate manner.
I should add that it is EMBO Journal policy to allow only a single round of revision and that acceptance of your manuscript will therefore depend on the completeness of your responses in this revised version.
When preparing your letter of response to the referees' comments, please bear in mind that this will form part of the Peer Review Process File, and will therefore be available online to the community. For more details on our Transparent Editorial Process, please visit our website: http://www.nature.com/emboj/about/process.html
We generally allow three months as standard revision time. As a matter of policy, competing manuscripts published during this period will not negatively impact on our assessment of the conceptual advance presented by your study. However, we request that you contact the editor as soon as possible upon publication of any related work, to discuss how to proceed.
Thank you for the opportunity to consider your work for publication. I look forward to your revision.
1. Care is needed with novel fold claim for Chs6. A lot of it looks like a helical solenoid, although more irregular and collapsed on itself than in most trafficking proteins. Details on the DALI output or other basis for the conclusion that the fold is novel should be provided.
2. The analogy between the FN3-BRCT fragment and the appendage domains from COPI and various clathrin adaptors is interesting, but I am not convinced it is functionally insightful or structurally justified. As the authors state, "the fold of the tandem FN3-BRCT domain is not identical to that of a canonical appendage domain" and "in contrast to other appendage domains, which bind accessory factors, we show that the primary role of the exomer appendage domain is to bind Arf1 for recruitment of exomer to membranes. Since both the structure and function of the domain are unrelated to appendage domains, I find it confusing at best and misleading at worst to refer to it as an appendage domain. I would suggest sticking to the term FN3-BRCT to describe this region. This comment implies that the title of the manuscript needs to be changed, perhaps to something along the lines of "Structure, Assembly and Membrane Recruitment of the Exomer Sorting Adaptor Complex". Minor 3. Figure S1 . The electron density should be shown for the experimental MIRAS map and for an omit map. The model-phased 2Fo-Fc map shown is cosmetically attractive because it is biased towards the model, but is not helpful for evaluating the quality of the structure determination.
4. Table S1 . More information on the heavy atom derivatives should be shown, for example the phasing power, anomalous phasing power, isomorphous R-factor, and Cullis R-factor for each derivative.
5. I am not sure the use of a separate chain identified for residues 4-48 is a good idea. I understand the intent is to avoid committing to an assignment the authors are uncertain of, but on the other hand, I think this will be confusing to users of the coordinate file who are expecting to see two molecules rather than three.
6. How much solvent-accessible surface area is buried between Chs5 and Chs6?
7. The domain-swapped heterotetramer model is interesting and plausible. Does the H25D/H26D mutation have a phenotype? (I am not suggesting that this experiment needs to be done, however, if
The EMBO Journal Peer Review Process File - EMBO-2012-82579 it hasn't been already.) 8. The structural movies are overused. Movies S2 and S3 are not needed.
Referee #2
Paczkowski et al. report the crystal structure of the Chs5/Chs6 sub-complex of the exomer, which is required for Golgi-to-plasma membrane transport of a subset of cargo in yeast. Structure-based mutagenesis is combined with in vitro biochemical and in vivo analyses to test structural predictions and clarify the nature of the interactions with Arf1 and membranes. Overall, this is a nicely executed study that reveals the core exomer architecture, including unexpected similarity of Chs5 to appendage domains of other coat complex adapters, and provides substantial insight into the structural basis for exomer recruitment to membranes. The manuscript is well written for the most part and would be appropriate for publication after minor modification.
p. 4 -"The linker between the a-helix and the FN3 domain is likely flexible ...". A statement to the effect that the linker has weak or otherwise uninterpretable density is needed for clarity. Fig. 2A -How was conservation calculated and what do "low" and "high" mean? Should be described in either the figure legend or methods.
In Fig. 2C , the Chs6 F63E/Q67E double mutant appears to disrupt binding whereas the individual mutations have little or no affect. This distinction should be stated clearly and discussed on p. 7. Perhaps also worth noting is the correlation of the affects of the single and double mutations on in vitro binding with the affects observed in the in vivo calcofluor sensitivity assay.
The molecular weights of the Chs5/6 complex determined by sedimentation velocity (205 kDa) and MALS (195 kDa) are substantially lower than the expected molecular weight for the tetrameric complex (240 kDa). This discrepancy contrasts with the close agreement between the MALS (117 kDa) and calculated (115 kDa) molecular weight for the dimeric complex in which the N-terminal bsheet of Chs5 is deleted. How do the authors interpret this result? A lower than expected molecular weight seems counterintuitive since common deviations due to aggregation or elongated shapes should yield larger than expected Stokes radii. Are the molecular weight determinations simply less accurate in the higher molecular weight range? Alternatively, is the size distribution for the Chs5/6 complex skewed by the presence of lower molecular weight proteolytic fragments (see Fig. 2C , for example) or perhaps related to the mixed species discussed in the context of the in vivo complex on p. 10?
Poor electron density for side chains located at a stable interface is unusual and may be additional evidence in favor of the "domain swapped" model. Given that there appears to be no a priori reason to pick the "non-domain swapped" model as the default (indeed there seem to be several caveats with that model), perhaps it would make more sense to present the (likely correct) "domain swapped" model in Fig. 1C and D, with an additional supplemental figure for the apparently less likely alternative. The ambiguity might be more definitively addressed by analyzing the effect of mutations in the relevant interfaces on the oligomeric state.
Referee #3
In this paper the authors determine the crystal structure of a functional sub-complex of the exomer cargo adaptor. The complex is comprised of a heterotetramer of Chs5 and Chs6 subunits, and the authors describe in detail the interaction surfaces among the subunits and demonstrate the necessity of the interactions for exomer function using yeast genetcs and cell biological assays. Most importantly, they find that Chs5 contains a domain resembling the appendage domains of the cargo adaptors on COPI and the clathrin APs, expanding an important structural priciple of adaptor proteins. They find that the Chs5 appendage domain directly binds Arf1 and in conjunction with other parts of the heterotetramer mediates Arf-dependent recruitment of exomer to TGN membranes. In addition, the appendage domain modulates Arf-GAP activity of the Arf-GAP Age2. Though the precise details are not worked out, this implies that the appendage domain may regulate the dynamics of vesicle formation and/or uncoating. The authors elucidate several key structural and functional similarities and differences between the Chs5 appendage domain and other cargo adaptor appendage domains.
In general, this paper reports a very novel structural and functional set of findings about cargo adaptors that should be of interest to anyone in the vesicle trafficking field and beyond. The data is exhaustive and mostly very straightforward to interpret. The authors are conservative and appropriate in their interpretation of data and speculation about its broader impacts. I am enthusiastic about this submission. (Please see next page.)
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Point-by-point Response to Referees
We are very appreciative of the enthusiasm of all three referees for our work. In this revised manuscript we have incorporated significant changes (two new supplementary figures, as well as many changes to the text) in response to the comments. We are therefore pleased to present an improved manuscript that we hope you will agree is now suitable for publication in The EMBO Journal. The most salient changes are to the Title of the manuscript, and that we no longer refer to the FN3-BRCT region of Chs5 as an appendage domain (see our detailed comments below in bold font).
Referee #1
Exomer is a specialized sorting adaptor involved in the trafficking of Chs3 and Fus1 from the trans-Golgi network to the plasma membrane. This study reports the crystal structure of the core complex comprising the ordered portion of Chs6 and all of Chs5. The structural ideas are corroborated by functional studies and accompanied by a thorough characterization of the assembly of the complex in solution and its interactions with Arf1 and lipid membranes. Short of a better understanding of how cargo is bound, the study is definitive in that it covers the structure and function of this complex from all angles. The scope of this study is highly appropriate for a broad-interest interdisciplinary journal. I recommend it enthusiastically for publication without any further experimental work, but I do have a number of suggestions for changes in the manuscript, some minor and some more significant. Major 1. Care is needed with novel fold claim for Chs6. A lot of it looks like a helical solenoid, although more irregular and collapsed on itself than in most trafficking proteins. Details on the DALI output or other basis for the conclusion that the fold is novel should be provided.
We now include the DALI output as an additional Table (Supplementary Table 2) , and include a topology diagram in Supplementary Figure 2F . We also now note in the manuscript (p. 6) that there is some resemblance to the helical solenoid folds of other trafficking proteins (though the interdigitation of helical repeats and embedding of the beta-sheet within the larger domain are what make it a unique fold). The top DALI hits all involve relatively short stretches of the Chs6 polypeptide (200 amino acids or less, representing <30% of the structure). We were initially excited by finding GGA3 as a hit, but further investigation indicated the structural similarity was restricted to just two TPR repeats.
2. The analogy between the FN3-BRCT fragment and the appendage domains from COPI and various clathrin adaptors is interesting, but I am not convinced it is functionally insightful or structurally justified. As the authors state, "the fold of the tandem FN3-BRCT domain is not identical to that of a canonical appendage domain" and "in contrast to other appendage domains, which bind accessory factors, we show that the primary role of the exomer appendage domain is to bind Arf1 for recruitment of exomer to membranes. Since both the structure and function of the domain are unrelated to appendage domains, I find it confusing at best and misleading at worst to refer to it as an appendage domain. I would suggest sticking to the term FN3-BRCT to describe this region. This comment implies that the title of the manuscript needs to be changed, -2012-82579 perhaps to something along the lines of "Structure, Assembly and Membrane Recruitment of the Exomer Sorting Adaptor Complex".
We now understand that our use of the term "appendage" was potentially misleading, as the FN3-BRCT domain is indeed structurally and functionally distinct from true appendage domains. We now use "FBE domain" (FN3-BRCT of exomer) when referring to this domain. The rationale for using an acronym is primarily convenience, as it is simpler to say or read FBE (three syllables) than FN3-BRCT (seven syllables). We did extensive literature and database searching and have found no other examples of FBE domains in the literature.
This change led us to make several modifications to the text and Figures. In particular:
1) The title of the work is now "The exomer cargo adaptor structure reveals a novel GTPase-binding domain".
2) In the Abstract, we now say that the architecture of the FBE domain is "reminiscent" of appendage domains, but has a distinct topology. We include this statement because several in the field have noted how striking the resemblance is, although of course we now realize there will be other experts such as yourself who disagree. Therefore, we hope you agree that we are now presenting this in a more balanced manner, by pointing out the resemblance but stating that they are not actually the same. It is not our goal to manufacture a similarity that does not exist, but we would be remiss to not draw some attention to the resemblance.
3) Throughout the text, we have replaced "similarity" with "resemblance" when describing the structural relationship between the two. Figure S1 . The electron density should be shown for the experimental MIRAS map and for an omit map. The model-phased 2Fo-Fc map shown is cosmetically attractive because it is biased towards the model, but is not helpful for evaluating the quality of the structure determination.
We have rectified this by creating a new Supplementary Figure 2, in which we show the same region of the following electron density maps: A) MIRAS phased map B) Solvent-flattened MIRAS phased map C) 2Fo-Fc map D) Simulated-annealing omit map
The EMBO Journal Peer Review Process File - EMBO-2012-82579 4. Table S1 . More information on the heavy atom derivatives should be shown, for example the phasing power, anomalous phasing power, isomorphous R-factor, and Cullis R-factor for each derivative.
We have now included the requested information in the Table. 5. I am not sure the use of a separate chain identified for residues 4-48 is a good idea. I understand the intent is to avoid committing to an assignment the authors are uncertain of, but on the other hand, I think this will be confusing to users of the coordinate file who are expecting to see two molecules rather than three.
These residues are now part of Chain A, together with the rest of the Chs5 polypeptide.
How much solvent-accessible surface area is buried between Chs5 and Chs6?
We now report this value (817 Å 2 ) on page 8.
7. The domain-swapped heterotetramer model is interesting and plausible. Does the H25D/H26D mutation have a phenotype? (I am not suggesting that this experiment needs to be done, however, if it hasn't been already.)
We agree that this is an interesting experiment, and we have initiated this type of analysis, but cannot report anything conclusive at this time. We are grateful the referee thinks that this is beyond the scope of the current work, in particular because it would likely involve establishing whether the mutants also affect multimerization in vivo, in addition to assessing the growth or Chs3-localization phenotypes.
8. The structural movies are overused. Movies S2 and S3 are not needed.
We have removed these two movies. Movie S4 has been renamed Movie S2.
Referee #2
p. 4 -"The linker between the a-helix and the FN3 domain is likely flexible ...". A statement to the effect that the linker has weak or otherwise uninterpretable density is needed for clarity.
The EMBO Journal Peer Review Process File - EMBO-2012-82579 We are assuming the linker is flexible based on its conformation in the structure, even though the density is largely interpretable (please see the Figure included at the end of this document). Our impression is that the specific main-chain and side-chain conformations seen in this region of the structure are dictated primarily by the crystal contact at the end of the BRCT domain, and that other configurations are likely possible. However, in order to clarify and better represent the uncertainty of this assertion, we have changed the sentence to read: "The linker between the α-helix and the FN3 domain may be flexible, as it consists of a glycine followed by three hydrophilic residues lacking regular secondary structure." (italics denote new text) Fig. 2A -How was conservation calculated and what do "low" and "high" mean? Should be described in either the figure legend or methods.
We used ConSurf, which calculates a "normalized conservation score". "Low" therefore represents the least conserved residues in the alignment, and "high" represents the most conserved residues in the alignment. This additional information is now presented in the Figure Legend.
In Fig. 2C , the Chs6 F63E/Q67E double mutant appears to disrupt binding whereas the individual mutations have little or no affect. This distinction should be stated clearly and discussed on p. 7….
Thank you for pointing out that this was not clear in the original manuscript. We have modified the text in the last paragraph on page 7.
…Perhaps also worth noting is the correlation of the affects of the single and double mutations on in vitro binding with the affects observed in the in vivo calcofluor sensitivity assay.
We have modified the first paragraph of page 8 to incorporate this suggestion.
The molecular weights of the Chs5/6 complex determined by sedimentation velocity (205 kDa) and MALS (195 kDa) are substantially lower than the expected molecular weight for the tetrameric complex (240 kDa). This discrepancy contrasts with the close agreement between the MALS (117 kDa) and calculated (115 kDa) molecular weight for the dimeric complex in which the N-terminal b-sheet of Chs5 is deleted. How do the authors interpret this result? A lower than expected molecular weight seems counterintuitive since common deviations due to aggregation or elongated shapes should yield larger than expected Stokes radii. Are the molecular weight determinations simply less accurate in the higher molecular weight range? Alternatively, is the size distribution for the Chs5/6 complex skewed by the presence of lower molecular weight proteolytic fragments (see Fig. 2C , for example) or perhaps related to the mixed species discussed in the context of the in vivo complex on p. 10?
Our interpretation is that the results are lower than expected either because of proteolysis, or else the complex may actually partially dissociate during its preparation. We now note these possibilities in the manuscript at the top of page 9.
Poor electron density for side chains located at a stable interface is unusual and may be additional evidence in favor of the "domain swapped" model. Given that there appears to be no a The EMBO Journal Peer Review Process File - EMBO-2012-82579 priori reason to pick the "non-domain swapped" model as the default (indeed there seem to be several caveats with that model), perhaps it would make more sense to present the (likely correct) "domain swapped" model in Fig. 1C and D, with an additional supplemental figure for the apparently less likely alternative. The ambiguity might be more definitively addressed by analyzing the effect of mutations in the relevant interfaces on the oligomeric state.
We agree that this provides additional evidence for the domain swap model. In order to address this suggestion, we have created a new Supplementary Figure 3 , which shows the alternative asymmetric unit (we confirmed that this model gives identical refinement statistics to the original model). We decided to continue to present the original asymmetric unit designation in Figure 1 , as we feel it is the more conservative choice of the two options.
Regarding the last comment about analyzing the effects of mutations in the relevant interfaces, we did attempt to distinguish between the two models using the HH/DD mutation that disrupts the tetramer but not the Chs5/6 heterodimer. We realize this analysis might be deemed incomplete, which is why we are cautious in our interpretation of this data. We have come to realize that it is very difficult to prove or disprove either the domain swap model or the alternative model by analysis of mutants, because it is hard to ascertain whether a mutation has simply destabilized the entire Chs5 N-terminus. We believe a definitive answer most likely will require additional structural studies.
Referee #3
In this paper the authors determine the crystal structure of a functional sub-complex of the exomer cargo adaptor. The complex is comprised of a heterotetramer of Chs5 and Chs6 subunits, and the authors describe in detail the interaction surfaces among the subunits and demonstrate the necessity of the interactions for exomer function using yeast genetics and cell biological assays. Most importantly, they find that Chs5 contains a domain resembling the appendage domains of the cargo adaptors on COPI and the clathrin APs, expanding an important structural priciple of adaptor proteins. They find that the Chs5 appendage domain directly binds Arf1 and in conjunction with other parts of the heterotetramer mediates Arfdependent recruitment of exomer to TGN membranes. In addition, the appendage domain modulates Arf-GAP activity of the Arf-GAP Age2. Though the precise details are not worked out, this implies that the appendage domain may regulate the dynamics of vesicle formation and/or uncoating. The authors elucidate several key structural and functional similarities and differences between the Chs5 appendage domain and other cargo adaptor appendage domains.
In general, this paper reports a very novel structural and functional set of findings about cargo adaptors that should be of interest to anyone in the vesicle trafficking field and beyond. The data is exhaustive and mostly very straightforward to interpret. The authors are conservative and appropriate in their interpretation of data and speculation about its broader impacts. I am enthusiastic about this submission.
Figure: (see Referee #2, point #1)
The linker between the Chs5 alpha-helix and FBE domains, shown with the 2Fo-Fc map contoured at 1.2 σ (wall-eyed stereodiagram). The FBE domain extends from the top of the image, whereas the exomer core extends from the bottom of the image. Thank you for sending us your revised manuscript. Referee 2 has now seen it again, and you will be pleased to learn that in his/her view you have addressed all criticisms in a satisfactory manner.
Prior to formal acceptance, there are a number of editorial issues that need further attention: * Please include the full PDB accession details into the main body of the manuscript text at this point.
* Please add scale bars & explanations to all microscopic pictures in the study (including the supplementary material) * Statistics: Please add the number of independent repeats to the legend of figure 5F . With respect to figure 5D and the fact that n=2 for the GST control, I need to ask you to either repeat the experiment once more or to include one representative value without error bars and state in the legend that one of two repeats is shown or to switch to a diagram that allows for the presentation of all individual data points in one column.
* We now encourage the publication of source data, particularly for electrophoretic gels and blots, with the aim of making primary data more accessible and transparent to the reader. Would you be willing to provide files comprising the original, uncropped and unprocessed scans of all gels used in the figures? We would need 1 file per figure (which can be a composite of source data from several panels) in jpg, gif or PDF format, uploaded as "Source data files". The gels should be labelled with the appropriate figure/panel number, and should have molecular weight markers; further annotation would clearly be useful but is not essential. These files will be published online with the article as a supplementary "Source Data". Please let me know if you have any questions about this policy.
Thank you for your kind cooperation.
Yours sincerely, Editor
The EMBO Journal
The revised manuscript is appropriate for publication. * Statistics: Please add the number of independent repeats to the legend of figure 5F . With respect to figure 5D and the fact that n=2 for the GST control, I need to ask you to either repeat the experiment once more or to include one representative value without error bars and state in the legend that one of two repeats is shown or to switch to a diagram that allows for the presentation of all individual data points in one column.
The number of repeats for figure 5F (n=3) has been added to the figure legend.
An additional experiment for the GST control was carried out and added to the previous data so that the number of repeats is now 3. New statistical analysis was performed (the results were virtually identical to the previous results).
The source data for each figure with gels or blots have been compiled into corresponding PDF files. It was not always possible to include molecular weight markers (for some gels this information was not documented).
